Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 9:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Systemic Lupus Erythematosus
Interventions: Placebo, Belimumab 1 mg/kg, Belimumab 10 mg/kg; Drug
Lead sponsor: Human Genome Sciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 819 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 67
States / cities: Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 56 more

Conditions: Healthy Volunteers
Interventions: AZD2373 subcutaneous injection, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Healthy Volunteers, C-Reactive Protein
Interventions: LY5625575, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 204 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Miami, Florida • Dallas, Texas

Conditions: Alzheimer's Disease, Dementia
Interventions: Drug: EVP-6124, Placebo; Drug
Lead sponsor: FORUM Pharmaceuticals Inc; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 42
States / cities: Tucson, Arizona • Little Rock, Arkansas • Culver City, California + 39 more

Conditions: Atopic Dermatitis
Interventions: CD2027 Ointment 3 mcg/g, twice daily, Vehicle Ointment, twice daily; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 14
States / cities: Hot Springs, Arkansas • San Diego, California • Denver, Colorado + 10 more

Conditions: Peripheral Artery Disease
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Rivaroxaban-Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 50 Years and older
Enrollment: 6,564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 105
States / cities: Alexander City, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 91 more

Conditions: Covid19
Interventions: Ampion, Standard of Care; Biological · Other
Lead sponsor: Ampio Pharmaceuticals. Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Colorado Springs, Colorado

Conditions: Lipoprotein(a)
Interventions: MK-7262, Enlicitide, Placebo for MK-7262, Placebo for enlicitide; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 24
States / cities: Alexander City, Alabama • Mobile, Alabama • Beverly Hills, California + 21 more

Conditions: Critical Illness, Physiological Stress, Delirium, Sleep Deprivation
Interventions: Sound reduction, Sound masking; Device
Lead sponsor: Brian Gehlbach; Other
Eligibility: 18 Years to 99 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Moderate to Severe Glabellar Frown Lines
Interventions: IncobotulinumtoxinA (Xeomin) (20 Units), Placebo; Drug
Lead sponsor: Merz Pharmaceuticals GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Englewood, Colorado • Aventura, Florida • Coral Gables, Florida + 5 more

Conditions: Dehydration
Interventions: Smart Water Bottle; Behavioral
Lead sponsor: Kennesaw State University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Kennesaw, Georgia

Conditions: Shift-work Disorder
Interventions: Active phototherapy, Control phototherapy, Cognitive Behavioral Therapy (CBT), Sleep education control; Behavioral
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Novi, Michigan

Conditions: Dementia, Alzheimer Disease, Caregiver Burden, Self Efficacy
Interventions: Learning Skills Together Intervention, Caregiver Healthy Living Intervention; Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Acne Rosacea
Interventions: ACCU-D1, Vehicle; Drug
Lead sponsor: Accuitis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Louisville, Kentucky • Austin, Texas

Conditions: Acne Vulgaris
Interventions: CLS001 Topical Gel, CLS001 Topical Gel Vehicle; Drug
Lead sponsor: Maruho Co., Ltd.; Industry
Eligibility: 12 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 20
States / cities: Encino, California • San Diego, California • Santa Monica, California + 17 more

Conditions: Lupus Nephritis
Interventions: Voclosporin High Dose, Voclosporin Low Dose, Placebo; Drug
Lead sponsor: Aurinia Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 14
States / cities: Los Angeles, California • Palo Alto, California • Gainesville, Florida + 11 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Efpeglenatide SAR439977, Placebo, Background therapy: Metformin alone or in combination with SU; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 23
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 20 more

Conditions: Pompe Disease (Late-onset), Glycogen Storage Disease Type II (GSD-II), Acid Maltase Deficiency Disease, Glycogenosis 2
Interventions: alglucosidase alfa, Placebo; Biological · Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 8 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 5
States / cities: Beverly Hills, California • Washington D.C., District of Columbia • St Louis, Missouri + 2 more

Conditions: Depression
Interventions: PEER Interactive Report; Device
Lead sponsor: MYnd Analytics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2016
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Epidermolysis Bullosa
Interventions: SD-101 dermal cream (3%), SD-101 Dermal Cream (6%), Vehicle (SD-101 0%); Drug
Lead sponsor: Scioderm, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 7
States / cities: Palo Alto, California • Chicago, Illinois • St Louis, Missouri + 4 more

Conditions: Gulf War Syndrome
Interventions: Curcumin, Glutathione, Placebo; Drug · Other
Lead sponsor: South Florida Veterans Affairs Foundation for Research and Education; Federal
Eligibility: 35 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hepatitis B
Interventions: Engerix™-B vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 20 Years and older
Enrollment: 667 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 10
States / cities: Huntsville, Alabama • Stockbridge, Georgia • Boise, Idaho + 7 more

Conditions: Myasthenia Gravis, Generalized
Interventions: Claseprubart, Placebo, Claseprubart, Placebo; Drug · Combination Product
Lead sponsor: Dianthus Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 4
States / cities: Pasadena, California • Boca Raton, Florida • Fayetteville, North Carolina + 1 more

Conditions: Affective Psychosis, Bipolar, Manic Disorder, Manic-Depressive Psychosis, Mania, Manic State, Psychoses, Manic-Depressive
Interventions: Quetiapine fumarate (Seroquel) SR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 51
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Cerritos, California + 48 more

Search by objective public record fields.

A Study of Belimumab in Subjects With Systemic Lupus Erythematosus

A Study to Assess Safety, Tolerability, PK and PD of AZD2373 in Healthy Male Participants of Sub-Saharan West African Ancestry

A Study of LY5625575 in Healthy Participants and in Participants With Inflammation (Elevated C-Reactive Protein)

Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress

A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)

Trial to Evaluate the Effects of Sound Modulation on Critically Ill Patients

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines

Efficacy of a Smart Water Bottle Intervention to Increase Fluid Consumption in College Students

Role of Sleep Reactivity in Shift Work Disorder

Learning Skills Together Family Caregiver Complex Intervention

Safety and Efficacy of ACU-D1 in the Treatment of Acne Rosacea

Safety and Efficacy Study of CLS001Topical Gel Compared to Vehicle in Subjects With Inflammatory Acne Vulgaris

AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea

A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease

Study to Evaluate the Safety and Efficacy of PEER Interactive to Inform Medication Prescription for Subjects With a Primary Diagnosis of Depression

Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa

Glutathione vs. Curcumin Clinical Trial

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus

A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)

Phase 3 /Seroquel SR Acute Mania Monotherapy - US